Dr. Qiming Wang earned his Ph.D. in Mammalian Genetics from Tufts University through a joint program with The Jackson Laboratory (JAX), where his research integrated human GWAS with murine transcriptomics to uncover genetic pathways in autoimmune disease.
He is currently Director of Product Strategy and Strategic Partnerships at Cyagen, leading the global expansion of Humanized Genomic Ortholog (HUGO) models and building strategic alliances to accelerate the translation of preclinical research into breakthrough therapies.
Dr. Liu earned his Ph.D. in Pharmacology and Therapeutics from University College Dublin and completed postdoctoral training in Neuroscience at the Cleveland Clinic, U.S.
With a strong foundation in biomedical research and extensive business development experience, Dr. Liu bridges academia and industry. He previously served as Senior Business Manager at leading biotechnology companies, including IASO Biotherapeutics and Symray Biopharma, where he drove marketing, strategic partnerships, and business development initiatives for cell therapies and antibody-based biologics.
Currently, Dr. Liu is responsible for strategic planning of industrial product lines and for expanding collaborations to deliver tailored solutions that drive customer success.
